Oxford BioDynamics
Plc
("OBD" or the
"Company" and, together
with its subsidiaries, the "Group")
PDMR Dealing / Grant of Share
Options
21
June 2024 - Oxford BioDynamics Plc
(AIM: OBD), a biotechnology company
developing precision medicine tests based on the EpiSwitch® 3D
genomics platform, announces that it has granted a total of 10,665,020
options over its ordinary shares of 1 pence each ("Ordinary
Shares"), to certain Group employees, including 10,150,020 options
to Chief Executive Officer, Dr Jon Burrows ("the Grant of
Options"). The options were granted under the Company's 2016
Employee Share Option Plan with an exercise
price of 9p per share.
One-third of the options granted to
Dr Burrows will vest and become exercisable on each of 23 March
2025, 23 March 2026 and 23 March 2027. Vested options will
remain exercisable up to and including the tenth anniversary of the
date of grant.
Following this grant, Dr Jon
Burrows, holds options over Ordinary Shares and is interested in
Ordinary Shares as follows:
|
|
Total
number of options over Ordinary Shares
|
Ordinary
Shares held
|
|
Number
|
% of
current issued share capital
|
|
Jon Burrows
|
12,773,734
|
1,088,888
|
0.35%
|
The Grant of Options constitutes a
related party transaction pursuant to AIM Rule 13. The independent
directors of the Company consider, having consulted with the
Company's nominated adviser, Shore Capital and Corporate Limited,
that the Grant of Options is fair and reasonable insofar as the
Company's shareholders are concerned.
The information set out below is
provided in accordance with the requirements of the UK Market Abuse
Regulation.
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Jon Burrows
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Director/PDMR
|
|
b)
|
Initial notification/
Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Oxford BioDynamics
Plc
|
|
b)
|
LEI
|
2138005Y1TK258O5U928
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of 1 pence
each
ISIN:
GB00BD5H8572
|
|
b)
|
Nature of the transaction
|
Grant of share options
|
|
c)
|
Price(s) and volume(s)
|
10,150,020 Ordinary Shares at an
exercise price of 9 pence per share
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
21 June 2024
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
For
further details please contact:
|
Oxford BioDynamics Plc
Jon Burrows, CEO
Paul Stockdale, CFO
|
Tel: +44 (0)1865
518910
|
|
Shore Capital
Nominated Adviser and Broker
Stephane Auton / Lucy
Bowden
|
Tel: +44 (0)20 7408
4090
|
|
Instinctif Partners
Melanie Toyne-Sewell / Katie Duffell
/ Jack Kincade
|
Tel: +44 (0)20 7457
2020
OxfordBioDynamics@instinctif.com
|
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is
a global biotechnology company, advancing personalized healthcare
by developing and commercializing precision medicine tests for
life-changing diseases.
It has two commercially available
products: the EpiSwitch®
PSE (EpiSwitch Prostate Screening test) and EpiSwitch®
CiRT (Checkpoint Inhibitor Response Test) blood tests.
PSE is a blood test that boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or
absence of prostate cancer, which has been launched in the US
and UK in September 2023. CiRT is a
predictive immune response profile for immuno-oncology (IO)
checkpoint inhibitor treatments, launched in February
2022.
The Company's product portfolio is
based on a proprietary 3D genomic biomarker platform, EpiSwitch®,
which can build molecular diagnostic classifiers for the prediction
of response to therapy, patient prognosis, disease diagnosis and
subtyping, and residual disease monitoring, in a wide range of
indications, including oncology, neurology, inflammation,
hepatology and animal health.
In March 2021, the Company launched
the first commercially available microarray kit for high-resolution
3D genome profiling and biomarker discovery, the
EpiSwitch Explorer Array
Kit which is available for
purchase by the life science research community.
OBD has participated in more than 40
partnerships with big pharma and leading institutions including
Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic,
Massachusetts General Hospital and Mitsubishi Tanabe
Pharma.
The Company has created a valuable
technology portfolio, including biomarker arrays, molecular
diagnostic tests, bioinformatic tools for 3D genomics and an
expertly curated 3D genome knowledgebase comprising hundreds of
millions of data points from over 15,000 samples in more than 30
human diseases.
OBD's group headquarters and
research, product development and UK clinical laboratories are
in Oxford, UK. It also has a commercial office
in Gaithersburg, MD, USA and a clinical laboratory
in Frederick, MD, USA, and a reference laboratory in
Penang, Malaysia.
The company is listed on the London
Stock Exchange's AIM, with ticker OBD. For more information, please
visit the Company's website, www.oxfordbiodynamics.com,
or follow OBD on X
(@OxBioDynamics)
and LinkedIn.
About EpiSwitch®
The 3D configuration of the genome
plays a crucial role in gene regulation. By mapping this
architecture and identifying abnormal configurations,
EpiSwitch® can be used to
diagnose patients or determine how individuals might respond to a
disease or treatment.
Built on over 10 years of research,
EpiSwitch® is Oxford Biodynamics' award-winning, proprietary
platform that enables screening, evaluation, validation and
monitoring of 3D genomic biomarkers. The technology is fully
developed, based on testing of over 15,000 samples in 30 disease
areas, and reduced to practice.
In addition to stratifying patients
with respect to anticipated clinical outcomes, EpiSwitch® data
offer insights into systems biology and the physiological
manifestation of disease that are beyond the scope of other
molecular modalities. The technology has performed well in academic
medical research settings and has been validated through its
integration in biomarker discovery and clinical development with
big pharma.
